Single-Center Study of Lymphoepithelioma-Like Carcinoma of Uterine Cervix over a 10-Year Period

Abstract

Background and objectives: Lymphoepithelioma-like carcinoma (LELC) is a histological type of malignant tumor arising from the uncontrolled mitosis of transformed cells originating in epithelial tissue. It is a rare subtype of squamous cell carcinoma of the uterine cervix. There are significant differences in frequency, mean age, viral status, and outcomes in Asian or Caucasian patients. Materials and Methods: A retrospective study of all cases of lymphoepithelioma-like carcinoma of the cervix at the Clinic of Oncogynecology, University Hospital, Pleven, Bulgaria between 1 January 2007 and 31 December 2016 was performed. All patients were followed-up till March 2019. We analyzed some clinical characteristics of the patients, calculated the frequency of lymphoepithelioma-like carcinoma of the cervix from all patients with stage I cervical cancer, and looked at the overall survival rate, the 5-year survival rate, and the correlation between overall survival, lymph node status, and the size of the tumor. Results: The frequency of lymphoepithelioma-like carcinoma was 3.3% for all cases with cervical carcinoma at stage I. The mean age of the patients with LELC was 49.6 years (range 32–67). Fourteen patients (82.4%) were in the FIGO IB1 stage, three patients (17.6%) were in the FIGO IB2 stage. Lymph nodes were metastatic in three patients (17.6%), non-metastatic in 13 patients (76.5%), and unknown in one patient. The overall survival rate was 76.47% for the study period and the 5-year survival rate of the patients that were followed-up until the 5th year (14 patients) was 69.23%. Conclusions: Lymphoepithelioma-like carcinoma is a rare SCC subtype, but it could be more frequent among western patients than previously thought. Our results do not confirm the data showing low risk of lymph metastasis and good prognosis of LELC, which is why we think that the treatment in these cases has to be more aggressive than is reported in the literature.

Lymphoepithelioma-like carcinoma of the uterine cervix: correlation with Epstein-Barr virus and human papillomavirus infection. A single-center experience

“…Most studies are reporting early stage of diagnosis in this tumor type and better prognosis compared to the most common types of cervical carcinoma [14,17]. The experience of our institution differs from those results, since the 5-year overall survival rate of our patients with LELC of uterine cervix as previously reported is 69.23% [29].…”

Колко Редки Са Редките Онкологични Болести?

“…По тази причина те не могат да бъдат представителни за България, но са най-голямата база данни, публикувана и анализирана до момента в България. В четири от статиите [13][14][15][16] обект на публикация са карциномите на маточната шийка с редки хистологични подвидове. Описани са техните морфологичнобиологични особености и значението им за клиничното поведение, като това е и най-голямата серия случаи, публикувани в литературата относно редки хистологични подвидове като lymphoepithelioma-like carcinoma (LELC) [14,17], мукоепидермоидния -MEC [16] и warty карцинома [13] на маточната шийка.…”

“…В четири от статиите [13][14][15][16] обект на публикация са карциномите на маточната шийка с редки хистологични подвидове. Описани са техните морфологичнобиологични особености и значението им за клиничното поведение, като това е и най-голямата серия случаи, публикувани в литературата относно редки хистологични подвидове като lymphoepithelioma-like carcinoma (LELC) [14,17], мукоепидермоидния -MEC [16] и warty карцинома [13] на маточната шийка. Честотата на тези карциноми е относително ниска, съответно 3.03%, 1.12% и 2.2%.…”

“…Честотата на тези карциноми е относително ниска, съответно 3.03%, 1.12% и 2.2%. Интересен е анализът за преживяемост сред тези пациентки като подобно на данните за редки онкогинекологични тумори, преживяемостта сред тези редки подвидове карциноми на маточна шийка е сходна с тази на нередките карциноми [13][14]16].…”

“…Обобщението на данните от България в погорецитираните публикации [12][13][14][15][16][17] допринася за по-лесно идентифициране на множество редки болести и дава възможност за тяхното адекватно лечение без допълнително забавяне поради редкия хистологичен подвид.…”